My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 96

    1.

    What are pharmacological chaperones and why are they interesting?

    Ringe D, Petsko GA.

    J Biol. 2009 Oct 13;8(9):80. No abstract available. PMID: 19833004 [PubMed - in process]Related articlesFree article

    2.

    Chemical and pharmacological chaperones as new therapeutic agents.

    Loo TW, Clarke DM.

    Expert Rev Mol Med. 2007 Jun 28;9(16):1-18. Review.PMID: 17597553 [PubMed - indexed for MEDLINE]Related articles

    3.

    Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs.

    Arakawa T, Ejima D, Kita Y, Tsumoto K.

    Biochim Biophys Acta. 2006 Nov;1764(11):1677-87. Epub 2006 Sep 1. Review.PMID: 17046342 [PubMed - indexed for MEDLINE]Related articles

    4.

    Why molecular chaperones buffer mutational damage: a case study with a yeast Hsp40/70 system.

    Bobula J, Tomala K, Jez E, Wloch DM, Borts RH, Korona R.

    Genetics. 2006 Oct;174(2):937-44. Epub 2006 Jul 18.PMID: 16849597 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Pharmacological chaperones: potential treatment for conformational diseases.

    Bernier V, Lagacé M, Bichet DG, Bouvier M.

    Trends Endocrinol Metab. 2004 Jul;15(5):222-8. Review.PMID: 15223052 [PubMed - indexed for MEDLINE]Related articles

    6.

    Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

    Yu Z, Sawkar AR, Whalen LJ, Wong CH, Kelly JW.

    J Med Chem. 2007 Jan 11;50(1):94-100.PMID: 17201413 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Pharmacological chaperones: a new twist on receptor folding.

    Morello JP, Petäjä-Repo UE, Bichet DG, Bouvier M.

    Trends Pharmacol Sci. 2000 Dec;21(12):466-9. Review.PMID: 11121835 [PubMed - indexed for MEDLINE]Related articles

    8.

    Chemical chaperones: mechanisms of action and potential use.

    Papp E, Csermely P.

    Handb Exp Pharmacol. 2006;(172):405-16.PMID: 16610368 [PubMed - indexed for MEDLINE]Related articles

    9.

    Molecular chaperones and selection against mutations.

    Tomala K, Korona R.

    Biol Direct. 2008 Feb 26;3:5. Review.PMID: 18298866 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Systems biology of molecular chaperone networks.

    Csermely P, Korcsmáros T, Kovács IA, Szalay MS, Soti C.

    Novartis Found Symp. 2008;291:45-54; discussion 54-8, 137-40.PMID: 18575265 [PubMed - indexed for MEDLINE]Related articles

    11.

    Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.

    Sloan LA, Fillmore MC, Churcher I.

    Curr Opin Drug Discov Devel. 2009 Sep;12(5):666-81. Review.PMID: 19736625 [PubMed - indexed for MEDLINE]Related articles

    12.

    Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells.

    Tropak MB, Mahuran D.

    FEBS J. 2007 Oct;274(19):4951-61. Review.PMID: 17894780 [PubMed - indexed for MEDLINE]Related articles

    13.

    Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro.

    Evans CG, Wisén S, Gestwicki JE.

    J Biol Chem. 2006 Nov 3;281(44):33182-91. Epub 2006 Sep 14.PMID: 16973602 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Pharmacological chaperone action on G-protein-coupled receptors.

    Bernier V, Bichet DG, Bouvier M.

    Curr Opin Pharmacol. 2004 Oct;4(5):528-33. Review.PMID: 15351360 [PubMed - indexed for MEDLINE]Related articles

    15.

    Molecular chaperones: biology and prospects for pharmacological intervention.

    Smith DF, Whitesell L, Katsanis E.

    Pharmacol Rev. 1998 Dec;50(4):493-514. Review. No abstract available. PMID: 9860803 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

    Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello JP, Bouvier M.

    EMBO J. 2002 Apr 2;21(7):1628-37.PMID: 11927547 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Inability of chaperones to fold mutant zeta crystallin, an aggregation-prone eye lens protein.

    Goenka S, Rao CM.

    Mol Vis. 2000 Nov 8;6:232-6.PMID: 11073557 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease.

    Egido-Gabás M, Canals D, Casas J, Llebaria A, Delgado A.

    ChemMedChem. 2007 Jul;2(7):992-4. No abstract available. PMID: 17479993 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

    Lieberman RL, D'aquino JA, Ringe D, Petsko GA.

    Biochemistry. 2009 Jun 9;48(22):4816-27.PMID: 19374450 [PubMed - indexed for MEDLINE]Related articles

    20.

    Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones.

    Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, Sorscher EJ, Bebok Z, Collawn JF.

    Biochem J. 2008 Mar 15;410(3):555-64.PMID: 18052931 [PubMed - indexed for MEDLINE]Related articlesFree article

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination
    Write to the Help Desk